MHRA green light for DemeRx’s opioid use disorder trial
Phase I portion of the trial will be conducted at the Manchester clinical unit of MAC Clinical Research
Read More
Tag: Opioid use disorder
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
